The Manufacturers Life Insurance Company Raises Stake in Qiagen (NYSE:QGEN)

The Manufacturers Life Insurance Company increased its stake in Qiagen (NYSE:QGEN) by 1.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,784 shares of the company’s stock after buying an additional 1,104 shares during the period. The Manufacturers Life Insurance Company’s holdings in Qiagen were worth $3,911,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QGEN. CWM LLC increased its position in shares of Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the period. Riverview Trust Co purchased a new position in Qiagen during the 1st quarter worth $28,000. Toronto Dominion Bank bought a new stake in Qiagen during the 2nd quarter valued at $27,000. Park Place Capital Corp purchased a new stake in shares of Qiagen in the 1st quarter worth $36,000. Finally, Quarry LP purchased a new stake in shares of Qiagen in the 4th quarter worth $38,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 0.6 %

NYSE:QGEN opened at $43.32 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The stock has a market capitalization of $9.89 billion, a P/E ratio of 29.05, a P/E/G ratio of 3.16 and a beta of 0.39. The company’s 50-day simple moving average is $45.38 and its 200-day simple moving average is $43.49. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.44.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same period in the previous year, the company earned $0.53 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. On average, equities analysts anticipate that Qiagen will post 2.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several research reports. JPMorgan Chase & Co. raised their price target on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, June 27th. Finally, Robert W. Baird upped their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.